[Inhibition of the blastomogenic effect of 7,12-dimethylbenz(a)anthracene in female rats by buformin, diphenin, a polypeptide pineal extract and L-DOPA].
Female rats were treated with buformin, phenytoin, polypeptide pineal extract, L-DOPA or buformin combined with L-DOPA during 3 weeks before intravenous injections of DMBA (1.5 mg 6 times with one-week intervals) over a period of carcinogen injections and after it till the animals' death. The overall tumour incidence in the control group was 97%, while in buformin, phenytoin, pineal extract, L-DOPA and buformin + L-DOPA treated groups it amounted to 55, 71, 80, 50 and 62%, respectively (P < 0.05). The incidence of mammary adenocarcinoma amounted to 81, 36, 55, 26, 25 and 19%, respectively (P < 0.05). The mechanisms of the similar effects the drugs belonging to different classes produce on chemical carcinogenesis are discussed.
D015127:9,10-Dimethyl-1,2-benzanthracene / Q000037:antagonists & inhibitors*; D000230:Adenocarcinoma / Q000517:prevention & control*; D000232:Adenofibroma / Q000517:prevention & control; D000818:Animals; D000970:Antineoplastic Agents; D001551:Benz(a)Anthracenes / Q000037:antagonists & inhibitors*; D002026:Buformin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005350:Fibroma / Q000517:prevention & control; D007980:Levodopa / Q000627:therapeutic use; D008325:Mammary Neoplasms, Experimental / Q000517:prevention & control*; D010455:Peptides / Q000302:isolation & purification / Q000627:therapeutic use; D010672:Phenytoin / Q000627:therapeutic use; D010870:Pineal Gland / Q000032:analysis; D051381:Rats
D000970:Antineoplastic Agents; D001551:Benz(a)Anthracenes; D010455:Peptides; D007980:Levodopa; D015127:9,10-Dimethyl-1,2-benzanthracene; D010672:Phenytoin; D002026:Buformin
Tormozhenie buforminom, difeninom, polipeptidnym ékstraktom épifiza i L-DOFA blastomogennogo éffekta 7,12-dimetilbenz(a)antratsena u krys-samok.